Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

AMICUS THERAPEUTICS INC Form 4 June 17, 2016		
FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 4 or	NERSHIP OF NERSHIP OF NERSHIP OF NERSHIP OF Number: 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5	
$\frac{\text{obligations}}{\text{may continue}}$ Section 17(a) of the	Section 16(a) of the Securities Exchang Public Utility Holding Company Act o of the Investment Company Act of 194	f 1935 or Section
1. Name and Address of Reporting Person <u>*</u> Barth Jay	2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS INC [FOLD]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last) (First) (Middle) C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2016	Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer
(Street) CRANBURY, NJ 08512	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 	
(City) (State) (Zip)	Table I - Non-Derivative Securities Acc	uired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Dee Execution any (Month/	· · · · · · · · · · · · · · · · · · ·	5. Amount of Securities6. Ownership Form: Direct7. Nature of IndirectBeneficially Owned(D) or Indirect (I)Beneficial OwnershipFollowing Following Transaction(s) (Instr. 3 and 4)(Instr. 4)
Common 06/15/2016 Stock	A 15,000 A \$0	46,374 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of 6. Date Exercisable orDerivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 D S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Options (right to buy)	\$ 6.1	06/15/2016		А	60,000	<u>(1)</u>	06/15/2026	Common Stock	60,000	

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships				
reprinting of their reality real of	Director	10% Owner	Officer	Other	
Barth Jay C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY, NJ 08512			Chief Medical Officer		
Signatures					

/s/ Jay Barth

06/17/2016

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate
(1) number of options granted, vests on June 15, 2017. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on July 1, 2017, with the final installment vesting on June 1, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.